Immunotherapy targeting the programmed death 1 (PD-1) receptor and its ligand (PD-L1) is also being studied for sarcomas, as are tyrosine kinase inhibitors due to their broad spectrum of inhibitory action on tumour angiogenesis and growth30,31. This evidence concerns the gene CD274 and sarcoma.